To assess the efficacy of a single oral dose of 5HT1A antagonist GSK958108 on ejaculation latency time (ELT) in male subjects suffering from premature ejaculation (PE).
INTRODUCTION AND OBJECTIVES:
To assess the efficacy of a single oral dose of 5HT1A antagonist GSK958108 on ejaculation latency time (ELT) in male subjects suffering from premature ejaculation (PE).
METHODS: A total of 35 male subjects were enrolled in a Phase 1 double-blind, placebo-controlled, parallel group masturbationmodel study. All 35 subjects completed the study. No subject was withdrawn from the study. There were no major protocol deviations reported during the study.
RESULTS: In the 3 mg GSK958108 treatment group, the ELT was estimated to be 16% longer (95% CI: -16% to þ61%) than if the subjects had taken placebo. In the 7 mg GSK958108 treatment group, the ELT was estimated to be 77% longer (95% CI: þ28% to þ144%) than in the placebo group. The systemic exposure to GSK958108 increased with dosage between 3 mg and 7 mg. A significant trend toward an increase of ELT was observed with increasing plasma concentrations of GSK958108. Headache was the most common adverse effect, reported by seven subjects (20%). There were no serious adverse events or deaths reported during the study.
CONCLUSIONS: This study indicates that 5HT1A antagonist GSK958108 3 mg day and 7 mg day was found to be well-tolerated, safe and effective for the treatment of PE subjects and demonstrated a strong association between 5HT1A receptors and ejaculation control in humans (NCT00861484) METHODS: Six patients with severe ED no longer responsive to oral and intracavernosal pharmacotherapy were treated. The mean age was 61AE5 years old. Serum testosterone and prolactin levels were normal in all patients, IIEF-5 ranged between 3 and 7 (mean 4.8). The penile dynamic Colour Duplex Doppler Ultrasound (D-CDDU) detected arteriogenic ED with Systolic Peak Velocity (PSV) between 18 and 25 cm/sec (mean 21.8). Penile rigidity was grade 1 on 4 according to Erection Hardness Score. Through a single or bilateral femoral percutaneous access, patients underwent selective angiography of internal iliac arteries and IPA. Angiographically significant stenosis of IPA (diameter obstruction >50%) were observed bilaterally in five patients and unilaterally in one. Stenosis were gradually dilated with 2.0/2.5x30/80 mm diameter medicated balloons. All patients were discharged one or two days after angioplasty on double antiplatelet therapy (clopidogrel 75 mg þ ASA 100 mg) and atorvastatin 40 mg die.
RESULTS: All procedures were successful in restoring of good IPA flow. No complications occurred. Patients were followed at 4 and 8 months. At the first check all patient reported a significant improvement in erections with an average increase of 9 points in the IIEF-5. Three patients had to use sildenafil 100 mg and three 50 mg to have good erections. D-CDDU detected an average increase of 13.5 cm/sec in PSV. At eight months, one patient was regressed at the initial state and underwent prosthesis placement; two patients had to use alprostadil 10 ugr and three had satisfactory erections using Sildenafil 100 mg.
CONCLUSIONS: IPA stenosis angioplasty with paclitaxel-eluting balloons seems to be a promising therapy for ED not responsive to pharmacotherapy. It is a safe and repeatable procedure, leads to improvement of erectile function in a good percentage of cases and should be considered as a last therapeutic opportunity before proposing a penile prosthesis.
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PD28-10 INCREASED PREPAREDNESS BEFORE RADICAL PROSTATECTOMY IS ASSOCIATED WITH BETTER PATIENT REPORTED POST-OPERATIVE SEXUAL OUTCOMES
Abhinav Khanna*, Anna Faris, Anna Zampini, Daniel Hettel, Hadley Wood, Bradley Gill, Edmund Sabanegh, Cleveland, OH INTRODUCTION AND OBJECTIVES: Radical prostatectomy significantly affects male sexual function. This study assessed the impact of pre-operative group education on preparedness for surgery and post-operative patient-reported sexual function outcomes.
METHODS: A group education seminar was offered to men undergoing radical prostatectomy between 2015-2017. Seminars were led by advanced practice providers with experience caring for men following prostatectomy. Patients were counseled on the expected perioperative course, including erectile dysfunction and expectations for sexual recovery. Patients completed surveys at baseline as well as by telephone at 3-weeks, 3-months, 6-months and 1-year post-operatively.
RESULTS: A total of 210 men underwent group education before prostatectomy. Of 147 men with intact baseline erectile function, follow-up surveys were completed by 92 (62.6%) at 3 weeks, 69 (46.9%) at 3 months, 48 (32.7%) at 6 months, and 36 (24.5%) at 1 year post-operatively. The proportion of men with partial or full erections increased over time from 20.7% at 3 weeks to 58.3% at 1 year (Figure 1) . Conversely, the proportion reporting post-operative erectile function "as expected" or better decreased from 56.8% at 3 weeks to 11.8% at 1 year. Notably, men who reported greater preoperative understanding that surgery may worsen erections were more likely to report their erections "as expected" or better after surgery (52.5% vs 0% at 3 months, p[0.006). Similarly, men who were most "prepared overall" before surgery were more likely to rate their erections "as expected" or better following prostatectomy (45.2% vs 0% at 6 months, p[0.003). Of note, among men with no erectile recovery, the proportion reporting erections "as expected" decreased from 48.5% at 3 weeks to 0% at 1 year (p<0.05).
CONCLUSIONS: Despite increased recovery of erections through 1 year after prostatectomy, patient-reported satisfaction with post-operative erectile function decreased over time. However, men with greater preparedness for surgery had better post-operative patient-reported sexual function relative to expectations. Increasing preparedness for prostatectomy by setting accurate expectations with preoperative education is associated with improved patient-reported sexual function outcomes.
